Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# Glycorex Transplantation AB: Glycorex Transplantation AB

## Sitemaps
[XML Sitemap](https://glycorex.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Pages
- [Our Products](https://glycorex.com/our-products/)
- [Investors](https://glycorex.com/investors/)
- [Innovation](https://glycorex.com/innovation/)
- [Publications](https://glycorex.com/publications/): HOME / PUBLICATIONS
- [Privacy Policy](https://glycorex.com/about-glycorex/privacy-policy/): HOME / PRIVACY POLICY (GDPR)
- [News](https://glycorex.com/news/): HOME / NEWS
- [Contact](https://glycorex.com/contact/): HOME / CONTACT
- [Board of Directors and CEO](https://glycorex.com/investors/board-of-directors-and-ceo/): HOME / INVESTORS / BOARD OF DIRECTORS AND CEO
- [Presentations](https://glycorex.com/investors/presentations/): HOME / INVESTORS / PRESENTATIONS
- [IR-contact](https://glycorex.com/investors/ir-contact/): HOME / INVESTORS / IR-CONTACT
- [Financial reports](https://glycorex.com/investors/financial-reports/): HOME / INVESTORS / FINANCIAL REPORTS
- [Financial calendar](https://glycorex.com/investors/financial-calendar/): HOME / INVESTORS / FINANCIAL CALENDAR
- [Corporate Governance](https://glycorex.com/investors/corporate-governance/): HOME / INVESTORS / CORPORATE GOVERNANCE
- [The Share – information](https://glycorex.com/investors/the-share-information/): HOME / INVESTORS / THE SHARE INFORMATION
- [Rheumatoid Arthritis](https://glycorex.com/innovation/rheumatoid-arthritis/): HOME / INNOVATION / RHEUMATOID ARTHRITIS
- [Patent](https://glycorex.com/innovation/patent/): HOME / INNOVATION / PATENT
- [Other projects](https://glycorex.com/innovation/other-projects/): HOME / INNOVATION / OTHER PROJECTS
- [Myastenhia Gravis](https://glycorex.com/innovation/myastenhia-gravis/): HOME / INNOVATION / MYASTENHIA GRAVIS
- [Transplants – living donors](https://glycorex.com/glycosorb-abo-en/transplants-living-donors/): HOME / PRODUCTS / GLYCOSORB® ABO / TRANSPLANTS LIVING DONORS
- [Transplants – deceased donors](https://glycorex.com/glycosorb-abo-en/transplants-deceased-donors/): HOME / PRODUCTS / GLYCOSORB® ABO / TRANSPLANTS DECEASED DONORS
- [Stem cell transplantations](https://glycorex.com/glycosorb-abo-en/stem-cell-transplantations/): Every year, more than 90,000 stem cell transplants are performed globally, of which about 45 percent are allogenic, i.e. the stem cells come from another person. Of these, about 20 percent have a blood group incompatibility which may cause serious complications and thus increase the risk of morbidity and mortality in the early phase after transplantation. Therefore, it is an advantage to use Glycosorb® ABO which is developed to specifically remove anti-A/B antibodies without any impact on the immune system. The results of Glycosorb® ABO in stem cell transplants are good, but experience is so far limited. If the long-term results are found to be in the same class as in blood group incompatible organ transplants, the potential for this product application is large.
- [Product information](https://glycorex.com/glycosorb-abo-en/product-information/): HOME / PRODUCTS / GLYCOSORB® ABO / PRODUCT INFORMATION
- [Unique technology platform](https://glycorex.com/innovation/unique-technology-platform/): HOME / INNOVATION / UNIQUE TECHNOLOGY PLATFORM
- [Clinical results](https://glycorex.com/clinical-results/): HOME / CLINICAL RESULTS
- [Market](https://glycorex.com/market/): HOME / MARKET
- [Market strategy](https://glycorex.com/about-glycorex/market-strategy/): For the European market, the strategy is to continue and expand direct sales of the company's products. Although the cost is higher than sales through distributors, it provides advantages in terms of higher margins and closer contact with customers as well as better control over the sales process.
- [About Glycorex](https://glycorex.com/about-glycorex/): HOME / ABOUT US
- [Glycosorb® ABO](https://glycorex.com/glycosorb-abo-en/): HOME / PRODUCTS / GLYCOSORB® ABO
- [Glycosorb® ABO 4ml](https://glycorex.com/glycosorb-abo-4ml-2/): The company’s product variant of Glycosorb® ABO for universal blood components is a unique medical device, designed for the specific reduction of anti-A/B antibodies in blood plasma without significantly affecting other antibodies or vital blood components.
- [Home](https://glycorex.com/): Glycorex’s unique molecular level technology that specifically selects and removes antibodies in the blood has opened up revolutionary treatments and solutions in healthcare. The company’s medical devices enable transplants across the blood groups saving lives and providing health economic benefits by increasing the number of transplants. The company’s technology to treat blood is applied in several health care settings and a new unique product has recently been launched with the potential to increase availability of blood plasma. Several revolutionary products for the treatment of autoimmune diseases are under development.

## Cision Posts
- [Glycorex Transplantation (GTAB B): enters into a distribution agreement in Brazil for Glycosorb® ABO](https://glycorex.com/cision/glycorex-transplantation-gtab-b-enters-into-a-distribution-agreement-in-brazil-for-glycosorb-abo/): Glycorex Transplantation AB continues its market expansion strategy by entering into an agreement with Grupo VIDA for the distribution rights to Glycosorb® ABO in Brazil.
- [Glycorex Transplantation AB (GTAB B): Delårsrapport januari – juni 2026](https://glycorex.com/cision/glycorex-transplantation-ab-gtab-b-delarsrapport-januari-juni-2026-2/): Kvartalet i korthet, april-juni 2026
- [Glycorex Transplantation (GTAB B): Signs distribution agreement in Malaysia for Glycosorb® ABO](https://glycorex.com/cision/glycorex-transplantation-gtab-b-signs-distribution-agreement-in-malaysia-for-glycosorb-abo/): Glycorex Transplantation AB (publ) continues its international expansion by enterering into a distribution agreement with OneMedik (M) SDN BHD, Malaysia.
- [Glycorex Transplantation (GTAB B): Signs distribution agreement in Argentina for Glycosorb® ABO](https://glycorex.com/cision/glycorex-transplantation-gtab-b-signs-distribution-agreement-in-argentina-for-glycosorb-abo/): As part of its continued international growth strategy, Glycorex Transplantation AB (publ) has entered into a distribution agreement with Buenos Aires-based Stone Fly Salud SA for the rights to Glycosorb® ABO (CE-marked) in Argentina.
- [JHLT-recognised ABO-incompatible paediatric transplant study](https://glycorex.com/cision/jhlt-recognised-abo-incompatible-paediatric-transplant-study/): Glycorex notes that a peer-reviewed scientific publication(1) on ABO-incompatible (ABOi) paediatric heart transplantation, conducted last year by Hollis et al. at Great Ormond Street Hospital (GOSH), London, has been selected by the editorial board of the Journal of Heart and Lung Transplantation (JHLT) as one of the journal’s top five most impactful papers of 2025.
 
The study retrospectively analysed paediatric heart transplants performed at GOSH between 2013 and 2023 and focuses on children aged 2–9 years undergoing ABO-incompatible heart transplantation. According to the publication, 14 children in this age group received an ABO-incompatible transplant during the study period, with a reported median follow-up time of 4.9 years.
 
Glycosorb® ABO has since 2015 been routinely used to facilitate ABO-incompatible transplantation at GOSH.
 
Dr Richard Issitt, Senior Paediatric Perfusionist, Great Ormond Street Hospital for Children states:
“ABO-incompatible heart transplantation using immunoadsorption has dramatically changed the landscape of paediatric heart transplantation. This study demonstrates the application to a far broader cohort of patients that originally envisioned, meaning more children are waiting less time for a new heart and a chance of a better future.” 
 
The authors have been invited to present the study on April 26 this year at the International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting in Toronto. The publication has also been featured by the JHLT Podcast editors as one of their selected studies of the year.
 
(1) Hollis, Paolo et al. ABO-incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant?
The Journal of Heart and Lung Transplantation, Volume 44, Issue 12, 1910 - 1917 For more information, please contact:
Johan Nilsson, CEO
Email: johan.nilsson@glycorex.com, Tel: +46 46 286 5230 Brief information about the company
Glycorex Transplantation AB (publ) is a global medical technology company headquartered in Sweden. The company has developed a unique medical technology (antigen-specific immunoadsorption) to specifically reduce blood group and autoantibodies in the blood.
The company's focus areas are within transplantation, blood transfusion, and autoimmune diseases. The company has sales in over 30 countries, with Europe as its largest market. Sales take place through own sales channels and in cooperation with distributors in selected markets. 
Product development and production takes place in the company’s own facility in Lund, Sweden.
Glycosorb® ABO is one of the company's self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplantation by specifically reducing anti-A/B antibodies in the organ recipient's plasma. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific publications have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Glycosorb® ABO has been used in more than 8,000 transplants in over 30 countries. 
The company has also developed and CE-marked a medical device variant of Glycosorb® ABO that targets a different customer segment: transfusion clinics and blood centers. The product can help increase the availability of universal blood components and has been shown to be effective for the preparation of low-titer blood plasma, whole blood, and platelet concentrate.
The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.
Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.
- [Glycorex Transplantation (GTAB B): First ABO-incompatible organ transplantion in Morocco with Glycosorb® ABO](https://glycorex.com/cision/glycorex-transplantation-gtab-b-first-abo-incompatible-organ-transplantion-in-morocco-with-glycosorb-abo/): The first ABO-incompatible kidney transplantion in Morocco has been successfully carried out following treatment with Glycosorb® ABO. The kidney transplant was performed from a related living donor - which is the primary application of Glycosorb® ABO - but the product is also increasingly used internationally to enable ABO-incompatible transplants of, for example, the liver and heart.
- [Glycorex Transplantation (GTAB B): Enters distribution agreement in Greece for Glycosorb® ABO in the field of transfusion and transplantation](https://glycorex.com/cision/glycorex-transplantation-gtab-b-enters-distribution-agreement-in-greece-for-glycosorb-abo-in-the-field-of-transfusion-and-transplantation/): Glycorex Transplantation AB (publ) is pleased to announce that the company has signed a distribution agreement with Rontis Hellas SA for the company’s product range, Glycosorb® ABO, in Greece, covering both products within transplantation and transfusion.
- [Glycorex Transplantation AB: First ABO-incompatible transplantation in Portugal with Glycosorb® ABO](https://glycorex.com/cision/glycorex-transplantation-ab-first-abo-incompatible-transplantation-in-portugal-with-glycosorb-abo/): Glycorex Transplantation AB (publ) announces that the first ABO-incompatible transplantation after treatment using the company’s product, Glycosorb® ABO, has recently been performed in Portugal.
- [Glycorex Transplantation AB (GTAB B): First blood group-incompatible pediatric heart transplantation in Austria using Glycosorb® ABO](https://glycorex.com/cision/glycorex-transplantation-ab-gtab-b-first-blood-group-incompatible-pediatric-heart-transplantation-in-austria-using-glycosorb-abo/): Glycorex Transplantation AB (publ) announce that the first blood group-incompatible heart transplantation in a child, using the company’s product Glycosorb® ABO, has been successfully carried out in Vienna, Austria.
- [Glycorex Transplantation AB (GTAB B): Results from Norwegian platelet evaluation presented at conference](https://glycorex.com/cision/glycorex-transplantation-ab-gtab-b-results-from-norwegian-platelet-evaluation-presented-at-conference/): As previously announced, a blood bank in Norway has evaluated our transfusion product, Glycosorb® ABO (4 ml), for the preparation of low-titer blood group O platelet concentrate with positive results. The findings were recently presented at a national transfusion conference in Norway.
- [Glycorex Transplantation AB: First ABO-incompatible transplantation in Argentina with Glycosorb® ABO](https://glycorex.com/cision/glycorex-transplantation-ab-first-abo-incompatible-transplantation-in-argentina-with-glycosorb-abo/): Glycorex Transplantation AB (publ) announces that the first ABO-incompatible transplantation after treatment using the company’s product, Glycosorb® ABO, has been successfully performed in Argentina.
- [Glycosorb® ABO is pushing the boundaries in paediatric blood group incompatible heart transplantation](https://glycorex.com/cision/glycosorb-abo-is-pushing-the-boundaries-in-paediatric-blood-group-incompatible-heart-transplantation/): In 2021, BBC wrote about Lucy, a 10-year-old girl, who is thought to be the oldest child in the world to receive a blood group incompatible heart (link). 
- [First publication from South Africa and first stem cell transplantation performed in Mexico](https://glycorex.com/cision/first-publication-from-south-africa-and-first-stem-cell-transplantation-performed-in-mexico/): Just over a year after Glycosorb® ABO was used for the first time in South Africa and on the African continent, the initial experience with our product in blood group incompatible kidney transplantation has been published1. The results are excellent.
- [Glycorex Transplantation (GTAB B): Signs agreement with distributor in Romania](https://glycorex.com/cision/glycorex-transplantation-gtab-b-signs-agreement-with-distributor-in-romania/): Glycorex Transplantation AB (publ) announces that the company has signed an agreement with a Romanian distributor for its product, Glycosorb® ABO.
- [Glycorex Transplantation AB: Entering into an agreement with Bio-Rad Laboratories, Inc.](https://glycorex.com/cision/glycorex-transplantation-ab-entering-into-an-agreement-with-bio-rad-laboratories-inc/): For more information, please contact:
- [Glycorex Transplantation AB (publ): Interim Report January – September 2023](https://glycorex.com/cision/glycorex-transplantation-ab-publ-interim-report-january-september-2023/): July – September 2023
- [Glycorex appoints Lars Juliusson as Business Development Manager Transfusion](https://glycorex.com/cision/glycorex-appoints-lars-juliusson-as-business-development-manager-transfusion/): Glycorex continues to build and strengthen the company and as part of this, Lars Juliusson has been recruited as Business Development Manager with the aim of leading the company's establishment in the field of transfusion medicine.
- [Glycorex Transplantation AB (publ): Interim Report January – March 2023](https://glycorex.com/cision/glycorex-transplantation-ab-publ-interim-report-january-march-2023/): January – March 2023
- [Annual Report 2022 Glycorex Transplantation AB (publ)](https://glycorex.com/cision/annual-report-2022-glycorex-transplantation-ab-publ/): Today Glycorex Transplantation AB (publ) publish the Annual Report for 2022. A pdf-version of the annual report in Swedish is enclosed to this press release. An English version will be available shortly on https://glycorex.com/investors/financial-reports/.
- [Published study from the US shows promising results on the use of Glycosorb® ABO to provide low-titer group O whole blood](https://glycorex.com/cision/published-study-from-the-us-shows-promising-results-on-the-use-of-glycosorb-abo-to-provide-low-titer-group-o-whole-blood/): The first pilot study on the use of Glycosorb® ABO for reducing anti-A/B antibody titers in blood group O whole blood has been published. The study was conducted at the University of Rochester, US. The use of Glycosorb® ABO effectively reduced the anti-A/B antibody titers to near zero without an increase in hemolysis. Glycosorb® ABO could be employed to provide low-titer group O whole blood reducing the need for type-specific blood which may expedite treatment and mitigate the risk of hemolysis from incompatible transfusion.
- [Year-end Report 2022](https://glycorex.com/cision/year-end-report-2022/): Increased sales in fourth quarter and full year.
- [The first blood group incompatible kidney transplant using Glycosorb® ABO performed in South Africa](https://glycorex.com/cision/the-first-blood-group-incompatible-kidney-transplant-using-glycosorb-abo-performed-in-south-africa/): In February 2023 the transplant team at the Groote Schuur Hospital in Cape Town, South Africa, as the first hospital on the African continent, performed a blood group incompatible kidney transplant using Glycosorb® ABO on a patient who had been on the transplant waiting list for almost 10 years. “The Groote Schuur Hospital transplant team are excited to be able to bring this technology to our patients, allowing more patients access to transplantation,” said Dr Zunaid Barday, Nephrologist at Groote Schuur Hospital.
- [Glycorex strengthens the organization to place additional force behind the growth strategy Going 4 Growth](https://glycorex.com/cision/glycorex-strengthens-the-organization-to-place-additional-force-behind-the-growth-strategy-going-4-growth/): On December 8, 2022, Johan Lavén took over as the new CEO of Glycorex with the task of implementing the company's growth strategy by expanding the company's operations in the transplant area globally, commercializing the company's product in universal blood plasma and initiating preparations for the clinical study of Glycorex's product for the treatment of rheumatoid arthritis. Since taking office, Johan, together with the Board of Directors, has conducted a review of the company's opportunities and decided to strengthen the organization in three central areas: marketing, sales, and quality work.
- [Glycorex Transplantation AB (GTAB B): Interim report January – September 2022](https://glycorex.com/cision/glycorex-transplantation-ab-gtab-b-interim-report-january-september-2022/): “After a strong second quarter, the third quarter of 2022 continued with good sales growth in most of the company’s markets. The development is in line with our long-term ambitions to create sustainable sales growth.”
- [Glycorex Transplantation (GTAB B): Glycosorb[®] ABO used at the largest heart transplant center in Germany](https://glycorex.com/cision/glycorex-transplantation-gtab-b-glycosorb-abo-used-at-the-largest-heart-transplant-center-in-germany/): Today, the Herz- und Diabeteszentrum Nordrhein-Westfalen in Bad Oeynhausen has announced in a press release that their first blood group incompatible heart transplant using Glycosorb® ABO has been performed and with excellent results. The transplant was performed on a two-year-old girl, and she has now been able to celebrate her two-year-old birthday at home. The girl came to the hospital five months ago as a result of an incurable genetic heart muscle disease and was put on the waiting list for transplant in July this year.
- [Glycorex Transplantation AB (GTAB B): Interim report January-June 2022](https://glycorex.com/cision/glycorex-transplantation-ab-gtab-b-interim-report-january-june-2022/): Accelerating sales growth
- [Glycorex Transplantation AB (publ) announces collaboration partner](https://glycorex.com/cision/glycorex-transplantation-ab-publ-announces-collaboration-partner/): Glycorex Transplantation AB (publ) has previously announced that the company is collaborating with a leading European research institute in order to develop a product for the treatment of the autoimmune disease, Rheumatoid arthritis (RA). Glycorex can today announce that this institute is University Hospital in Toulouse (UHT).
- [Quarterly Report, Quarter 1 2022](https://glycorex.com/cision/quarterly-report-quarter-1-2022/): The quarter in brief, January - March 2022
- [Glycorex Transplantation AB (GTAB B) expand its business in South America](https://glycorex.com/cision/glycorex-transplantation-ab-gtab-b-expand-its-business-in-south-america/): New Distributor appointed in Chile
- [Glycorex Transplantation sponsors a digital symposium on intraoperative Glycosorb[®] ABO-treatment in pediatric blood group incompatible heart transplantation](https://glycorex.com/cision/glycorex-transplantation-sponsors-a-digital-symposium-on-intraoperative-glycosorb-abo-treatment-in-pediatric-blood-group-incompatible-heart-transplantation/): Today, March 29, 2022, Glycorex Transplantation is sponsoring a symposium at IPTA 2022 to highlight the unique method developed by Great Ormond Street Hospital (GOSH) in London.
- [Glycorex Transplantation AB (publ.) Announces Appointment of Head of Sales.](https://glycorex.com/cision/glycorex-transplantation-ab-publ-announces-appointment-of-head-of-sales/): Lund, Sweden, March 7, 2022 – Glycorex Transplantation AB, a commercial stage medical device company, today announces Mr. Erik Melgaard Pedersen as the company’s Head of Sales. In this role, Mr. Pedersen will oversee all commercial activities for the company as we continue to expand globally.
- [Glycorex Transplantation (GTAB B): Concludes agreement with distributor in South Africa](https://glycorex.com/cision/glycorex-transplantation-gtab-b-concludes-agreement-with-distributor-in-south-africa/): Glycorex Transplantation AB (publ) can announce that the company has entered into an agreement with a distributor in South Africa for the company's transplant product, Glycosorb® ABO.
- [Geert Nygaard has joined Glycorex Transplantation AB (publ.) as Chief Executive Officer](https://glycorex.com/cision/geert-nygaard-has-joined-glycorex-transplantation-ab-publ-as-chief-executive-officer/): As previously announced, Geert Nygaard has joined Glycorex Transplantation AB (publ.) as its CEO as per 15th December 2021.
- [Glycorex Transplantation AB: Geert Nygaard appointed as new CEO](https://glycorex.com/cision/glycorex-transplantation-ab-geert-nygaard-appointed-as-new-ceo/): Glycorex Transplantation AB can announce that Geert Nygaard has been appointed as Chief Executive Officer of the company and will begin serving in that role on December 15th, 2021.
- [Manufacturing of low titer-blood group O whole blood: Presentation of results at the SABM 2021 Annual Meeting](https://glycorex.com/cision/manufacturing-of-low-titer-blood-group-o-whole-blood-presentation-of-results-at-the-sabm-2021-annual-meeting/): Glycorex Transplantation AB (publ.), listed on NGM Main Regulated Equity, announces that the Transfusion unit at the University of Rochester Medical Center presents their experience with the UBP-product for the manufacturing of low titer-blood group O whole blood (LTOWB) at the Society for the Advancement of Blood Management (SABM) today. 
- [UBP product: Presentation of results at the Jahrestagung DGTI](https://glycorex.com/cision/ubp-product-presentation-of-results-at-the-jahrestagung-dgti/): Glycorex Transplantation AB (publ.), listed on NGM Main Regulated Equity, announces that the transfusion unit at the University Hospital of Regensburg today presents its first experience with the UBP-product as a poster at the Jahrestagung der Deutschen Gesellschaft für Transfusionsmedizin und Immunohämatologie (DGTI).
- [Glycorex Transplantation AB (GTAB): Interim Report April-June 2021](https://glycorex.com/cision/glycorex-transplantation-ab-gtab-interim-report-april-june-2021/): Net sales increased 143% and significantly improved operating income.
- [Glycorex Transplantation AB (GTAB B): Universal Whole Blood: Presentation of results at two U.S. blood conferences](https://glycorex.com/cision/glycorex-transplantation-ab-gtab-b-universal-whole-blood-presentation-of-results-at-two-u-s-blood-conferences/): As previously announced, a leading center in the U.S. has tested our UBP-product for the manufacturing of universal whole blood. We can now announce that the results will be presented as poster presentations at the Society for the Advancement of Blood Management (SABM) and the AABB. In connection with these, abstracts will also be published in two different medical journals: "Anesthesia and Analgesia" and "Transfusion".
- [Publication shows significant benefits of using intraoperative Glycosorb[®] treatment for blood group incompatible pediatric heart transplants](https://glycorex.com/cision/publication-shows-significant-benefits-of-using-intraoperative-glycosorb-treatment-for-blood-group-incompatible-pediatric-heart-transplants/): Great Ormond Street Hospital for Children (GOSH) in London, UK, has been using Glycosorb ABO in conjunction with pediatric blood group incompatible heart transplants since 2015. GOSH has now in a retrospective study compared blood group incompatible transplants performed with Glycosorb ABO and plasma exchange. 
- [Glycorex Transplantation AB (GTAB): Interim Report January-March 2021](https://glycorex.com/cision/glycorex-transplantation-ab-gtab-interim-report-january-march-2021/): Sales recovery after weak start
- [Glycorex Transplantation AB (GTAB B) – publication of Annual Report 2020](https://glycorex.com/cision/glycorex-transplantation-ab-gtab-b-publication-of-annual-report-2020/): Today Glycorex Transplantation AB (publ) publishes the Annual Report for 2020 (in Swedish only). The Annual Report is attached to this press release and is also available on www.glycorex.com.
- [Glycorex Transplantation AB launches new website](https://glycorex.com/cision/glycorex-transplantation-ab-launches-new-website/): Glycorex Transplantation launches a new website available at www.glycorex.com. This is an important first step in increasing external communication and visibility in the market and making it easier for customers, partners and investors to find relevant information